Stockscreener 앱 받기
147.53
1.74%
2.53
시장 영업 전:
147.53
전일 마감가:
$145.00
열려 있는:
$145
하루 거래량:
692.13K
Relative Volume:
0.69
시가총액:
$14.71B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
50.01
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
-4.24%
1개월 성능:
+4.02%
6개월 성능:
+16.58%
1년 성능:
+8.94%
1일 변동 폭
$145.00
$148.45
1주일 범위
$141.00
$155.23
52주 변동 폭
$84.23
$160.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
147.53 | 14.46B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
123.78 | 53.87B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 47.07B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.97 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 34.82B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
513.79 | 22.27B | 3.08B | 1.24B | 1.07B | 25.61 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine’s valbenazine misses Phase III goals in DCP - The Pharma Letter
Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal - Nasdaq
Neurocrine's movement disorder treatment fails late-stage trial - marketscreener.com
Neurocrine's Phase 3 Trial of Valbenazine in Dyskinetic Cerebral Palsy Fails to Meet Primary, Key Secondary Endpoints - marketscreener.com
Neurocrine’s phase 3 trial for cerebral palsy drug fails to meet endpoints - Investing.com
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy - PR Newswire
Neurocrine Biosciences (NBIX): Assessing Valuation After New Phase 2 Bipolar I Mania Trial Launch - simplywall.st
Assenagon Asset Management S.A. Sells 13,280 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine’s Ingrezza Keeps Growing, But The Stock Has Lagged - Finimize
What hedge fund activity signals for Neurocrine Biosciences Inc. stock2025 Valuation Update & Weekly Sector Rotation Insights - Bölüm Sonu Canavarı
How Neurocrine Biosciences Inc. stock valuations compare to rivals2025 Volatility Report & Fast Gaining Stock Reports - Улправда
Merger Talk: Can Neurocrine Biosciences Inc. stock beat analyst upgrades2025 EndofYear Setup & Risk Managed Investment Entry Signals - moha.gov.vn
Is Neurocrine Biosciences (NBIX) Quietly Recasting Its Long-Term Story Around Metabolic Disease Innovation? - simplywall.st
How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easing2025 Earnings Surprises & Low Risk Entry Point Tips - ulpravda.ru
How Neurocrine Biosciences Inc. stock performs in weak economyQuarterly Earnings Summary & Weekly Hot Stock Watchlists - Улправда
Nxera Knocked Back As Boehringer Bows Out Of Schizophrenia Pact - Citeline News & Insights
Is Neurocrine Biosciences Inc. (NB3) stock a momentum leaderPortfolio Gains Summary & Technical Pattern Recognition Alerts - DonanımHaber
Why Neurocrine Biosciences Inc. stock is favored by pension fundsQuarterly Market Summary & Growth Focused Entry Point Reports - DonanımHaber
Neurocrine Bio. stock price target raised to $198 by H.C. Wainwright - Investing.com Canada
Published on: 2025-12-18 16:31:37 - Улправда
RBC Capital Keeps Their Buy Rating on Neurocrine (NBIX) - The Globe and Mail
HC Wainwright & Co. Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares - MarketBeat
Neurocrine Biosciences Director Sells Shares - TradingView — Track All Markets
Neurocrine Bio. stock price target reiterated at $200 by TD Cowen - Investing.com Canada
Key facts: HC Wainwright maintains 'Buy' on Neurocrine; price target rises - TradingView — Track All Markets
Neurocrine Bio. stock holds Buy rating at Jefferies after R&D Day - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Neurocrine Bio. stock rating reiterated at Outperform by RBC Capital - Investing.com Canada
Texas Permanent School Fund Corp Sells 11,976 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine showcases R&D across neuroscience and endocrinology - The Pharma Letter
Neurocrine Bio. stock holds steady as BMO reiterates $147 price target - Investing.com UK
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology - PR Newswire
What analysts say about Neurocrine Biosciences Inc stockMomentum Trading Signals & Free Daily Top Stock Picks for All Investors - earlytimes.in
Dir Norwalk Files To Sell 11,250 Of Neurocrine Biosciences Inc [NBIX] - TradingView — Track All Markets
Hudson Bay Capital Management LP Has $9.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns - simplywall.st
Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Boone Capital Management LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX is Braidwell LP's 3rd Largest Position - MarketBeat
Ieq Capital LLC Buys 35,956 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Mizuho raises Neurocrine Bio. stock price target to $175 on Crenessity outlook - Investing.com India
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by California Public Employees Retirement System - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Armistice Capital LLC - MarketBeat
Stifel Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Stifel Nicolaus Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Neurocrine Biosciences chief legal officer Lippoldt sells $698k in stock - Investing.com Canada
Neurocrine Bio. stock rating reiterated at Buy by TD Cowen - Investing.com Canada
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
0.65%
자본화:
|
볼륨(24시간):